Literature DB >> 8262747

Pharmaceutical properties, biodistribution, and imaging characteristics of manganese-mesoporphyrin. A potential hepatobiliary contrast agent for magnetic resonance imaging.

U P Schmiedl1, J A Nelson, D H Robinson, A Michalson, F Starr, T Frenzel, W Ebert, G Schuhmann-Giampieri.   

Abstract

OBJECTIVES: Manganese (III) mesoporphyrin (Mn-mesoporphyrin) was investigated for its pharmaceutical properties and magnetic resonance imaging characteristics as a potential hepatobiliary contrast agent.
METHODS: Solubility, partition coefficient, plasma binding, proton relaxation enhancement, biodistribution, biliary excretion, liver extraction ratio, and liver enhancement were measured in various in-vitro and in-vivo systems.
RESULTS: Mn-mesoporphyrin was soluble and stable at moderate alkaline pH in phosphate buffer. The octanol/water coefficient was 25.98, and the compound was highly protein bound. R1 for water and plasma were 1.94 and 2.35 L/mmol sec, respectively. R1 in liver was calculated to be 15.72 L/mmol sec. Biodistribution studies in rats and mice confirmed hepatotrophic properties and biliary excretion was 65% over 24 hours. First pass liver uptake was 15%. Magnetic resonance imaging studies showed persistent liver enhancement at 0.05 mmol/kg.
CONCLUSION: Mn-mesoporphyrin is a lipophilic compound that shows potential as a hepatobiliary magnetic resonance contrast agent.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8262747     DOI: 10.1097/00004424-199310000-00013

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  5 in total

1.  Manganese-based MRI contrast agents: past, present and future.

Authors:  Dipanjan Pan; Anne H Schmieder; Samuel A Wickline; Gregory M Lanza
Journal:  Tetrahedron       Date:  2011-11-04       Impact factor: 2.457

Review 2.  Revisiting an old friend: manganese-based MRI contrast agents.

Authors:  Dipanjan Pan; Shelton D Caruthers; Angana Senpan; Ann H Schmieder; Samuel A Wickline; Gregory M Lanza
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2010-09-21

3.  Development of a lipoprotein based molecular imaging MR contrast agent for the noninvasive detection of early atherosclerotic disease.

Authors:  L M Mitsumori; J L Ricks; M E Rosenfeld; U P Schmiedl; C Yuan
Journal:  Int J Cardiovasc Imaging       Date:  2004-12       Impact factor: 2.357

Review 4.  Chemistry of MRI Contrast Agents: Current Challenges and New Frontiers.

Authors:  Jessica Wahsner; Eric M Gale; Aurora Rodríguez-Rodríguez; Peter Caravan
Journal:  Chem Rev       Date:  2018-10-16       Impact factor: 60.622

Review 5.  Current trends in pyrrole and porphyrin-derived nanoscale materials for biomedical applications.

Authors:  Parinaz Fathi; Dipanjan Pan
Journal:  Nanomedicine (Lond)       Date:  2020-09-25       Impact factor: 5.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.